MicroRNAs and the response of prostate cancer to anti-cancer drugs

Marzia Pennati, Marco Folini, Paolo Gandellini, Nadia Zaffaroni

Research output: Contribution to journalArticlepeer-review


Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level-in PCa, together with their potential to simultaneously regulate multiple on-cogenic/tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.

Original languageEnglish
Pages (from-to)257-265
Number of pages9
JournalCurrent Drug Targets
Issue number3
Publication statusPublished - 2016


  • Anti-cancer drugs
  • MicroRNA
  • Prostate cancer

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'MicroRNAs and the response of prostate cancer to anti-cancer drugs'. Together they form a unique fingerprint.

Cite this